



7th Annual Private Equity Southeast Asia Summit

7-9 March 2012 | Singapore

www.private-equityseasia.com

[Home](#)[Intelligence](#)[Dealscope](#)[Deals](#)[League Tables](#)[Profiles](#)[PE Portfolio](#)[IPO](#) NEW[corporate site >>](#)[New Search](#) | [Last Search](#)**Intelligence: Results**[\[Select Page\]](#)[\[Deselect Page\]](#)[\[Print Selected\]](#) [\[Print All\]](#) [\[Download Selected\]](#) [\[Download All\]](#) 06/02/2012**Reviva Pharmaceuticals in discussions to partner novel molecule RP5063 for schizophrenia; Phase II under way – CEO**

Proprietary Intelligence

Story

Reviva Pharmaceuticals, a privately held San Jose, California-based pharmaceutical company, is currently in discussions with established pharma to partner its novel molecule RP5063 for schizophrenia and schizoaffective disorder, CEO Dr Laxminarayan Bhat said.

Its lead compound RP5063 is currently in Phase II trial and the company expects it to be complete by October 2012, he noted. The trial is being conducted in 228 patients with acute schizophrenia and schizoaffective disorder over a four-week, random-double blind placebo control. This multi-center global Phase II trial comprises patients in the US, India, Philippines, Malaysia, and Russia.

Reviva is hoping to partner the molecule for co-development and commercialization as soon as possible and is open to approaches regarding global and regional partnerships, Bhat noted.

The Phase I trial for RP5063 completed in California in September 2011 showed preliminary efficacy and proof of concept, he said. The company expects to file an NDA by the end of 2014, he added.

Bhat emphasized the quick turnaround from Phase I completion to Phase II enrollment, which took three months. The industry standard is typically nine to 12 months, he noted.

Moreover, Reviva has two molecules in pre-clinical stage – RP1000 for obesity and RP6000 for depression – that it will also look to partner going forward, the CEO said.

The company has a portfolio of New Chemical Entities (NCEs) designed in-house, and all NCEs are developed to act on validated targets for the treatment of chronic diseases with unmet medical needs. It is currently focused on developing drugs for the central nervous system (CNS), cardiovascular (CV), infectious, metabolic, and inflammatory diseases, according to its website.

Reviva was founded by Bhat in 2006, and shareholders include angel investors comprising medical doctors and professionals associated with the pharmaceutical and high-tech industries. It would like to eventually become a fully integrated pharmaceutical company, the CEO said.

by Mai Mizuta in Tokyo

Source Proprietary Intelligence**Value****Stake Value** N/A**Target** Reviva Pharmaceuticals [DS](#)**Sectors** Biotechnology
Medical
Medical: Pharmaceuticals**SubSectors** Biotechnology related research
Drug development**Topics** Advisory Invitation (Bankers, Other)
Joint Ventures/Partnerships**Intel Type** Companies for sale
Cross Border
Licensing/Financing**Countries** USA**Intel. Grade** Confirmed**Intelligence ID** 1310266[\[Select Page\]](#)[\[Deselect Page\]](#)[\[Print Selected\]](#) [\[Print All\]](#) [\[Download Selected\]](#) [\[Download All\]](#)

Intelligence: Alert Result Summaries

[View Selected](#)[View All](#)[Print Selected](#)[Print All](#)[Report Selected](#)[Report All](#)

Medical: Pharmaceuticals

 Reviva Pharmaceuticals in discussions to partner novel molecule RP5063 for schizophrenia; Phase II under way – CEO [Companies for sale, Cross Border, Licensing/Financing](#)